alexa
Reach Us +441234923305

GET THE APP

Interview | Raghu TadagavadinbspClinical Pharmacology a
ISSN: 2167-065X

Clinical Pharmacology & Biopharmaceutics
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Raghu Tadagavadi
Raghu Tadagavadi

Raghu Tadagavadi
Department of Medicine
Penn. State University College of Medicine
USA
Read Interview session with Raghu Tadagavadi

 
Biography

Raghu Tagadavadi is a Veterinary graduate with a master degree in Immunology from India, and PhD in Biochemistry and Molecular Biology with specialization in Immunotoxicology and Immunopharmacology from Pennsylvania State University College of Medicine, PA. He has 5 yrs of postdoctoral experience and 6 yrs of doctoral experience in Immunotoxicology, and 4 yrs clinical experience in Veterinary Medicine. He is also a Diplomate of the American Board of Toxicology (DABT). He also serves as a reviewer to many reputed journals in the areas of Immunology and Immunotoxicology, such as Plos One, Cytokine, British Journal of Pharmacology, American Journal of Nephrology, American Journal of Physiology, and others.

 
Research Interest

Pharmacology, Nephrotoxicity

Interview
1. How many years have you been practicing and/or performing research?
15 yrs.

2. What is the research topic you are working on now?
Immunology, Toxicology, Immunotoxicology, Immunopharmacology.

3. What makes an article top quality?
Understanding the problem in great detail. Designing and executing appropriate experiments.

4. What are the qualities you look for in an article?
Review of literature, appropriate experiments, and proper conclusion.

5. Do you have any research funding (NIH or other national funding) now?
Working on proposals.

6. When did you become an editor of OMICS Journal?
2013

7. What is your greatest career accomplishment?
Showing the role of dendritic cells in drug induced toxicity.

8. How does the research published percolate through to practitioners?
-

9. What is the purpose of serving as an editor?
To have more knowledge in the relevant field, and contributing for the betterment of known field of science.

10. Do you have any patents?
No

11. Have you contributed any editorials or papers (any types) to OMICS Journals in the past two years?
Yes (clinical and experimental pharmacology).

12. Do you plan to contribute any editorials or papers to OMICS Journals in the next year?
Yes

13. Do you have any trouble with OMICS Journals in the past?
No

14. Would you recommend OMICS to your friends or colleagues?
Yes

15. How do you differentiate Journal, Clinical Pharmacology & Biopharmaceutics with other journals in the field?
It is a new emerging Journal that publishes articles pertaining to Pharmacology, however, it needs more work for better recognition.
Top